S'abonner

Predictors of weight change in overweight patients with myocardial infarction - 15/08/11

Doi : 10.1016/j.ahj.2007.06.006 
Yazid Y. Fadl, MD, MPH a, Harlan M. Krumholz, MD, SM b, Mikhail Kosiborod, MD c, d, Frederick A. Masoudi, MD, MSPH e, f, Pamela N. Peterson, MD e, Kimberly J. Reid, MS c, William S. Weintraub, MD g, Donna M. Buchanan, PhD c, John A. Spertus, MD, MPH c, d,
a Washington University in St. Louis, St. Louis, MO 
b Yale University, New Haven, CT 
c Mid America Heart Institute of St. Luke's Hospital, Kansas City, MO 
d University of Missouri-Kansas City, Kansas City, MO 
e University of Colorado Health Sciences Center, Denver, CO 
f Denver Health Medical Center, Denver, CO 
g Christiana Care Health Services, Newark, DE 

Reprint requests: John A. Spertus, MD, MPH, Mid America Heart Institute of Saint Luke's Hospital, 5th floor, 4401 Wornall Road, Kansas City, MO 64111.

Résumé

Background

Weight loss is recommended among overweight survivors of myocardial infarction (MI). This study describes patterns of weight change among overweight patients with MI and identifies factors associated with weight change.

Methods

A prospective cohort of 1253 overweight or heavier (body mass index [BMI] ≥25 kg/m2) post-MI patients were enrolled in the 19-center PREMIER study and followed up for 1 year to determine changes in weight. Patients were categorized at 1 month as overweight (BMI = 25-29.9 kg/m2), obese (BMI = 30-39.9 kg/m2), or morbidly obese (BMI ≥40 kg/m2). Unadjusted percent weight change was assessed at 1 year, and multivariable linear regression was used to identify independent correlates of change.

Results

Mean weight change was −0.2% and varied by the severity of baseline obesity (+0.4% for overweight patients, −0.5% for obese patients, and −3.7% for morbidly obese patients [P < .001]). Multivariable analyses revealed the following to be significantly associated with weight change: depression 1 month post-MI (+2.7%, P = .001), lack of health insurance (+2%, P = .01), smoking cessation 1 month post-MI (+2.7% vs current smokers, P < .001), morbid obesity (+4.7% vs overweight patients, P < .0001), and increasing age (−0.8% per decade, P = .001). An interaction between smoking cessation and weight class was detected in that overweight patients who quit had a mean increase of 5.3% (95% CI 3.1%-7.4%), whereas no significant change was observed among obese and morbidly obese patients who quit.

Conclusions

Although post-MI patients had negligible weight loss over 1 year, several sociodemographic, clinical, and lifestyle characteristics were associated with weight change. New, targeted interventions will likely be needed to improve weight management after an MI.

Le texte complet de cet article est disponible en PDF.

Plan


 This work was supported by CV Therapeutics, Palo Alto, CA, and CV Outcomes, Inc (Kansas City, MO). Dr Spertus discloses that he has leadership responsibilities for CV Outcomes, Inc, Health Outcomes Sciences, and Outcomes Instruments; is a consultant for Amgen and United Healthcare; receives research grant support from the National Institutes of Health, Amgen, Lilly, Roche Diagnostics, and the American College of Cardiology-National Cardiovascular Data Registry; owns the copyrights for the Seattle Angina Questionnaire, the Kansas City Cardiomyopathy Questionnaire, and the Peripheral Artery Questionnaire; and previously received grant support and was a consultant for CV Therapeutics. Dr Masoudi discloses he has served on advisory boards for Takeda NA, Amgen, and United Healthcare; has contracts with the Oklahoma Foundation for Medical Quality; and is an associate editor of Journal Watch Cardiology of the Massachusetts Medical Society. Dr Krumholz discloses that he has research contracts with the Colorado Foundation for Medical Care and the American College of Cardiology, serves on the advisory boards for Amgen, Alere, and UnitedHealthcare, is a subject matter expert for VHA, Inc, and is editor-in-chief of Journal Watch Cardiology. No other authors have conflicts of interest to disclose related to this article.


© 2007  Mosby, Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 154 - N° 4

P. 711-717 - octobre 2007 Retour au numéro
Article précédent Article précédent
  • Exercise capacity and quality of life after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: Results from the Autologous Stem cell Transplantation in Acute Myocardial Infarction (ASTAMI) randomized controlled trial
  • Ketil Lunde, Svein Solheim, Svend Aakhus, Harald Arnesen, Torbjørn Moum, Michael Abdelnoor, Torstein Egeland, Knut Endresen, Arnfinn Ilebekk, Arild Mangschau, Kolbjørn Forfang
| Article suivant Article suivant
  • PPAR? gene C161T substitution is associated with reduced risk of coronary artery disease and decreased proinflammatory cytokine expression
  • Yu Liu, Zuyi Yuan, Yan Liu, Jijun Zhang, Ping Yin, Dongqi Wang, Yanni Wang, Chiharu Kishimoto, Aiqun Ma

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.